Clin Mol Hepatol.
2026 Jan;32(1):170-183. 10.3350/cmh.2025.0857.
Incretin-based therapies for cardio-kidney-liver-metabolic disease: the role of the liver in the modern era of chronic disease management
- Affiliations
-
- 1Storr Liver Centre, Westmead Institute for Medical Research, Westmead Hospital and The University of Sydney, Westmead, NSW, Australia
- 2MASLD Research Center, University of California San Diego, San Diego, CA, USA
- 3Division of Gastroenterology and Hepatology, Department of Medicine, National University Hospital, Singapore
- 4Saarland University Medical Center, University of the Saarland, Homburg, Germany and PharmaScienceHub (PSH), Saarbrücken, Germany
- 5MAFLD Research Center, Department of Hepatology, the First Affiliated Hospital of Wenzhou Medical University, Wenzhou, China
- 6Division of Gastroenterology and Hepatology, Houston Methodist Hospital, Houston, TX, USA
- 7Department of Medicine, Division of Endocrinology, Beth Israel Hospital, Harvard Medical School, Boston, MA, USA
- KMID: 2575365
- DOI: http://doi.org/10.3350/cmh.2025.0857
Abstract
- Steatotic liver disease (SLD) is a leading cause of disease globally and demands new therapeutic approaches to mitigate underlying metabolic dysregulation. Incretin-based therapies are emerging as a viable prospect to fulfil this unmet niche. A literature review to inform the evidence base for incretin focussed pharmacology in the metabolic liver diseases space and an informed commentary on unmet areas of need. Incretin-based therapeutics demonstrate multifarious benefits across the chronic metabolic disease spectrum with promising data across the continuum of pathology.
- Full Text Links
-
- Actions
-
Cited
- CITED
-
- Close
- Share
-
- Similar articles
-
- Pharmacological Therapy for Metabolic DysfunctionAssociated Steatotic Liver Disease in a New Era for Obesity and Metabolic Medicine: A State-of-the-Art Review
- Obesity Management in Primary Care: Clinical Approaches and Policy Implications in the Era of Incretin-Based Therapies
- Pharmacological treatment of metabolic dysfunction–associated steatotic liver disease: a narrative review
- Therapeutic landscape evolution for steatotic liver disease: from lifestyle interventions to precision pharmacotherapy
- Clinical impact of nonalcoholic fatty liver disease on other medical diseases
